Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $7.66, for a total transaction of $87,684.02. Following the transaction, the director now owns 7,229,861 shares in the company, valued at approximately $55,380,735.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total transaction of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total transaction of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total transaction of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total transaction of $106,457.10.
• On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.58, for a total transaction of $212,171.32.

Recursion Pharmaceuticals Trading Down 0.9 %

NASDAQ RXRX opened at $7.40 on Friday. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.54 and a twelve month high of $16.75. The firm’s 50 day moving average price is $10.79 and its two-hundred day moving average price is $9.09.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The firm had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. KeyCorp lifted their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. TD Cowen assumed coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They issued a “market perform” rating on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.75.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank boosted its stake in shares of Recursion Pharmaceuticals by 7.6% during the 1st quarter. Swiss National Bank now owns 94,300 shares of the company’s stock valued at $675,000 after buying an additional 6,700 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Recursion Pharmaceuticals by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock valued at $2,676,000 after buying an additional 6,294 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock valued at $458,000 after buying an additional 22,833 shares during the period. Rhumbline Advisers boosted its stake in shares of Recursion Pharmaceuticals by 4.0% during the 1st quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock valued at $887,000 after buying an additional 4,818 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 8.1% during the 1st quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock valued at $47,338,000 after buying an additional 497,504 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.